BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $11,701.66 in Stock
BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 521 shares at $22.46 each, totaling $11,701.66. Post-sale, he holds 308,486 shares valued at approximately $6.93 million, marking a 0.17% decrease in ownership. The stock recently traded down 2.2% to $21.83. BioLife reported $0.04 EPS for the last quarter, exceeding estimates, with revenue of $23.94 million. Analysts have a consensus rating of "Moderate Buy" with an average price target of $31.17. Institutional investors own 93.24% of the stock.
BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 521 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $22.46, for a total transaction of $11,701.66. Following the transaction, the executive vice president now directly owns 308,486 shares in the company, valued at $6,928,595.56. The trade was a 0.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Get BioLife Solutions alerts:
BioLife Solutions Trading Down 2.2%
- Best Biotech Stocks to Invest in Now
BLFS stock traded down $0.49 on Friday, reaching $21.83. The company's stock had a trading volume of 786,262 shares, compared to its average volume of 389,140. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market cap of $1.04 billion, a PE ratio of -20.59 and a beta of 2.01. The business has a fifty day simple moving average of $22.94 and a two-hundred day simple moving average of $25.09. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The firm had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. As a group, research analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.
Institutional Trading of BioLife Solutions
- 3 Small-Cap Medical Stocks Moving Markets Today
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. acquired a new stake in shares of BioLife Solutions in the first quarter worth approximately $30,789,000. Raymond James Financial Inc. acquired a new position in shares of BioLife Solutions during the 4th quarter worth about $20,664,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at about $19,805,000. Royal Bank of Canada raised its stake in BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock valued at $15,948,000 after acquiring an additional 617,320 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of BioLife Solutions during the 4th quarter worth approximately $11,113,000. 93.24% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
BLFS has been the topic of several research reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.17.
Read Our Latest Report on BioLife Solutions
BioLife Solutions Company Profile
(Get Free Report)BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Read More
- Five stocks we like better than BioLife Solutions
- The How And Why of Investing in Oil Stocks
- Nike’s Amazon Expansion Could Signal a Turnaround in 2025
- 3 Tickers Leading a Meme Stock Revival
- Intel’s Turnaround May Be the Best Bet No One’s Watching
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Defense Stocks That Will Profit From a Golden Dome
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in BioLife Solutions Right Now?
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
